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Background: Conventional proteomic approaches have thus far been unable to identify novel serum biomarkers for
ovarian cancer that are more sensitive and specific than the current clinically used marker, CA-125. Because endogenous
peptides are smaller and may enter the circulation more easily than proteins, a focus on the low-molecular-weight region
may reveal novel biomarkers with enhanced sensitivity and specificity. In this study, we deciphered the peptidome of
ascites fluid from 3 ovarian cancer patients and 3 benign individuals (ascites fluid from patients with liver cirrhosis).
Results: Following ultrafiltration of the ascites fluids to remove larger proteins, each filtrate was subjected to solid phase
extraction and fractionated using strong cation exchange chromatography. The resultant fractions were analyzed using
an Orbitrap mass spectrometer. We identified over 2000 unique endogenous peptides derived from 259 proteins. We
then catalogued over 777 peptides that were found only in ovarian cancer ascites. Our list of peptides found in ovarian
cancer specimens includes fragments derived from the proteins vitronectin, transketolase and haptoglobin.
Conclusions: Peptidomics may uncover previously undiscovered disease-specific endogenous peptides that warrant
further investigation as biomarkers for ovarian cancer.
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The advent of high-throughput, mass spectrometry-
based proteomics for biomarker discovery was met with
optimism over a decade ago. The ability to accurately
capture and catalogue numerous proteins in a given
sample was thought to hold great potential, and many
felt that next-generation biomarkers for various cancers
would be in the clinic within a few years. Unfortunately,
conventional “bottom-up” proteomics has thus far been
unable to uncover novel serum-based markers that are
more sensitive and specific than existing markers such
as prostate-specific antigen for prostate cancer and
carbohydrate antigen 125 (CA-125) for ovarian cancer
(OvCa) [1]. Conventional proteomic approaches have
struggled to overcome a number of inherent limitations to
biomarker discovery, namely the low relative abundance
of potential markers (which often exist in concentrations* Correspondence: vathany.kulasingam@uhn.ca
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unless otherwise stated.up to ten million-fold lower than circulating high-
abundance proteins [2]), and the enormous heterogeneity
of secreted proteins across samples, sub-populations, and
disease sub-types [3,4].
Ultimately, the difficulties that conventional proteomics
has faced in addressing these confounds necessitated the
exploration of alternate approaches to biomarker discovery.
The focus of several research groups has recently turned to
the low-molecular-weight (LMW) region, or peptidome, of
biological fluids. Previously billed as a “treasure trove of
diagnostic potential” [5], this region represents a rich
source to mine for new biomarkers. The rationale is that
proteolytic degradation products will make their way from
interstitial fluid, to lymph, to the bloodstream (where they
would ultimately be assayed) more easily than their larger
protein counterparts [6,7]. Since proteolytic activity likely
increases with the progression of malignancy, we expect to
find a wealth of degradation products in the cancerous state
[6]. Progression of malignancy is also associated with the
degradation of adhesion and cell-to-cell junction proteins,
and proteolytic products of these proteins are likely to be
differentially expressed in cancer, both intracellularly and in
the circulation, thereby marking the disease state.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tidomic approaches. Villanueva et al. found that a specific
signature of serum peptides was able to distinguish patients
with 3 different types of solid tumours from those without
cancer [8]. The group suggested that exoprotease activity
contributes to the generation of cancer-specific (and even
cancer type-specific) peptides in serum. More recently,
Fiedler et al. employed peptidomic profiling in a search for
pancreatic cancer markers, identifying two mass spectro-
metric peaks that were able to distinguish patients from
healthy controls with a sensitivity of 86.3% and a specificity
of 97.6% [9].
In this study, we applied a novel peptidomics approach to
ascites fluid originating from OvCa. Our work joins a small
but growing body of existing studies on the use of peptides
for OvCa diagnostics. Lopez et al. found several peptide
biomarker panels that could differentiate stage 1 ovarian
cancer patients from age-matched controls [10]. Similarly,
Fredolini et al. reported 59 peptide markers differentially
expressed in OvCa patients compared to patients with
benign gynecological conditions [2]. Unlike the above-
mentioned studies, which examined the peptidome of
serum, our study mined ascites fluid, an excellent choice
for biomarker discovery work. Since ascites fluid accumula-
tion occurs close to the target tissue (proximity to disease is
high), the fluid contains many cells of tumour origin, as
well as soluble factors released by both tumour cells and
the local microenvironment. Microenvironmental factors
are important since putative biomarkers can originate from
interactions between the tumour and the surrounding en-
vironment as well as from the cancerous tissue itself.
Despite significant research gains, there continues to be
an urgent need for novel biomarkers of ovarian cancer.
Early detection can close the gap between diagnosis at early
stages (which carries a five-year survival rate of up to 95%)
and diagnosis at later stages (with a five-year survival rate
of 10-30%) [11]. The existing clinically accepted serum
marker for ovarian cancer is CA-125, which, despite its
widespread use for monitoring therapeutic response, is not
sensitive or specific enough for early diagnosis. Other stud-
ied markers, including HE4, osteopontin, CA 15–3, CA
19–9, and various human tissue kallikreins, show utility in
detecting ovarian cancer, but none are effective for screen-
ing or early diagnosis [12,13]. The low-molecular-weight
proteome might uncover previously undiscovered alterna-
tives worthy of investigation. Our study identified over one
thousand peptides in ovarian cancer ascites (many of which
were expressed uniquely in cancer) that warrant further
verification and validation in future studies.
Results and discussion
Peptidome identification
Using the experimental workflow depicted in Figure 1, we
elucidated the endogenous peptidome of 6 ascites fluidsamples, 3 from OvCa patients and 3 from non-cancer con-
trols. This is, to our knowledge, the first study to mine the
low-molecular-weight region of OvCa ascites. We identified
2066 unique peptides (Additional file 1), 777 of which were
found in OvCa but not in the control samples. The 777
OvCa-specific peptides corresponded to only 59 proteins,
indicating that many of the peptides identified are degrad-
ation products of the same parent proteins. The list of the
59 parent proteins and the corresponding 777 unique pep-
tides is provided in Additional file 2A and B. A full
spectrum report, which includes information about modifi-
cations associated with each peptide, is provided in
Additional file 3. Figure 2 (A) and (B) display the overlap of
identified proteins and peptides between the benign and
OvCa samples, respectively. Interestingly, our study identi-
fied a larger number of peptides from benign samples than
from OvCa samples, suggesting that protease activity alone
may not be sufficient to discriminate cancerous from be-
nign ascites fluid. Our benign ascites fluid originated from
patients with cirrhosis of the liver, a condition associated
with a rise in both inflammatory mediators and matrix
metalloproteases [14-17].
Reproducibility across all six samples
Figure 3 (A) and (B) shows the overlap of identified pep-
tides and proteins, respectively, within the group of 3 OvCa
samples and the group of 3 benign samples. About 37-39%
of peptides and 50-58% of proteins were found in at least 2
samples. These data are to be expected if we consider the
biological heterogeneity of these samples (they all came
from different individuals).
Overlap with previously-delineated OvCa ascites
proteome
Kuk et al. previously mined the proteome of OvCa ascites,
identifying 445 proteins by combining mass spectrometry
data from multiple size exclusion and fractionation proto-
cols [18]. Of the 142 parent proteins we found in OvCa as-
cites (including the 23 proteins common to the control
cohort) (Figure 2), 73 were also found by Kuk et al. This
significant overlap (51%) corroborates our original hypoth-
esis that many endogenous peptides are derived from pro-
teins already present in the mid- to high-molecular-weight
region of ascites (>10 kDa). Given that our peptides were
endogenous degradation products, while Kuk et al.’s pep-
tides resulted from trypsin digestion of large proteins, we
expected to see little overlap at the peptide level. Indeed,
only 24 of 4585 total peptides identified were common to
both studies. This lends support to our experimental proto-
col’s ability to identify novel, endogenous peptides.
Overlap with existing OvCa serum proteome studies
Fredolini et al. compared the low-molecular-weight
serum proteome of 20 early-stage epithelial ovarian
Figure 1 Outline of experimental workflow (peptidomic analysis). The workflow consisted of the following: sample processing, followed by
strong cation exchange and reverse-phase chromatography coupled online to an LTQ-Orbitrap mass spectrometer and subsequent data analysis.
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tients with benign gynecological conditions [2]. From
our OvCa ascites samples, we identified 12 of the 59
serum proteins deemed overexpressed in OvCa by
Fredolini et al. Since serum is an entirely different bio-
logical fluid, this relatively low rate of overlap (20.3%) is
unsurprising. Another study, by Lopez et al., examined
the serum proteome of 110 healthy individuals and 430
OvCa patients (stages I-IV) [10]. The authors identified
160 proteins overexpressed in OvCa patients compared
to healthy controls. Our study identified 13 of theseproteins, which represents an overlap of 8.1%. Two of
these common proteins, transthyretin and apolipoprotein
A1, are components of the five marker, FDA-approved
OVA1 panel for discriminating cancerous from non-
cancerous ovarian masses [12].
Overlap with existing urine peptidomes
Smith et al. (manuscript submitted) delineated the pepti-
dome of 6 late-stage OvCa and 6 healthy urine samples
(each processed in triplicate), identifying 3646 peptides
from 514 proteins in the 6 ovarian cancer samples. We
Figure 2 Overlap of the proteins (A) and peptides (B) identified in benign (n = 3) and ovarian cancer (OvCa) (n = 3) ascites samples.
Fifty-nine unique proteins were found in the OvCa ascites fluid and 777 peptides were unique to OvCa ascites compared to benign controls
(ascites fluid from liver cirrhosis patients).
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ascites samples, as well as 29 common peptides. The
very low overlap at the peptide level (less than 1%) may
reflect the fluid-specificity of both proteins and prote-
ases. Smith et al. may have found entirely different pep-
tides in urine either because different proteases act in
the renal system and in urine, or because differentpeptides make their way into the urine as compared to
ascites. Either way, this preliminary finding may hint at
differences in how peptides are processed by the circula-
tory and renal systems at different stages and in different
fluids. Moreover, peptides are considered unique by
Scaffold if they differ by as little as one amino acid, and
this stringency could also limit the number of unique
Figure 3 Biological repeatability at the peptide (A) and protein (B) level across the 3 benign and 3 ovarian cancer (OvCa) ascites
samples. Overlap of unique peptides (A) and corresponding parent proteins (B) identified amongst (i) the three benign control ascites samples
and (ii) the three OvCa ascites samples. These samples represent biological replicates (not technical replicates). Each sample was analyzed
in singleton.
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domes. The 29 common peptides derive from 10 pro-
teins, the majority of which are high-abundance
proteins.
Siwy et al. compiled a human urinary peptide database
from healthy individuals [19]. Of the 114 proteins they
identified, we found 35. At the peptide level, we only
found 12 common peptides. This result may further cor-
roborate the fluid-specificity of proteins and proteases.
A six-way comparison of identified proteins in the
current study and in each of the studies cited above is
provided in Additional file 4.
Ovarian cancer-specific candidates
We filtered our list of identified proteins to select only
those proteins for which we identified peptides exclusively
(or almost exclusively) in the three ovarian cancer samples
(Table 1). Common high-abundance serum proteins were
excluded, with the exception of haptoglobin, whose differ-
ing proteolytic cleavage pattern between cancerous and
benign samples merits further study (as outlined below).We arrived at a final list of 12 proteins we deem most
worthy of further verification and validation, separated
into three categories: those previously studied as ovarian
cancer biomarkers, those previously studied in ovar-
ian cancer (including in gene expression studies) but
not as biomarkers, and those never before studied in
ovarian cancer.Candidates previously studied as ovarian cancer biomarkers
Out of our top 12 candidates, five proteins have been
previously examined as ovarian cancer biomarkers.
Below, we briefly describe each of these five proteins
and their association with OvCa. We identified endogen-
ous peptide fragments of Retinol-binding protein 4,
which has been previously studied in ovarian cancer
(using proteomic 2-D electrophoresis), and was sug-
gested to have potential as a diagnostic or prognostic
marker at the protein level [20]. Interestingly, the cited
study found decreased, not increased, levels of the pro-
tein in the sera of epithelial ovarian cancer patients.
Table 1 List of top protein/peptide candidates identified in ovarian cancer ascites fluid
Parent protein # of peptides (OvCa) # of peptides (Benign)
Retinol-binding protein 4 1 0
Serum paraoxonase/arylesterase 1 14 0
Talin-1 2 0
Isoform 1 of ficolin-3 1 0
Vitronectin 31 7
Apolipoprotein F precursor 12 1
Isoform 1 of Vitamin D-Binding protein 21 0
Histidine-rich glycoprotein 16 0
Transketolase (highly similar cDNA) 4 0
Mannosidase 2 0
EGF containing fibulin-like extracellular matrix protein 1 3 0
Haptoglobin 47 0
Number of total unique peptides identified (for each candidate parent protein) in the three ovarian cancer ascites samples (OvCa) and the three benign ascites
samples. Thresholds for high-confidence peptide identifications were set to ensure that false discovery rate (FDR) at the peptide level was close to 1%.
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Serum paraoxonase and arylesterase (another one of our
peptide candidates) in the sera of ovarian cancer patients
[21]. Several polymorphisms of the corresponding gene,
PON1, have been associated with increased risk of ovarian
cancer [22,23].
Our third candidate was Vitamin D-Binding Protein. A
recent study found that serum levels of this protein in ovar-
ian cancer did not differ significantly from levels in healthy
controls or individuals with benign conditions [24]. We
confirmed this upon preliminary verification using an
ELISA and found that serum levels of Vitamin D-binding
protein showed little ability to discriminate patients with
ovarian cancer from healthy controls (data not shown).
Our candidate list includes peptides derived from an
isoform of ficolin-3. Serum ficolin-3 was previously
found to be overexpressed in the sera of ovarian cancer
patients [25].
Finally, the potential utility of histidine-rich glycoprotein
to discriminate ovarian cancer has been previously re-
ported [26]. A two-marker panel of this protein along
with corticosteroid-binding globulin (not found in our
study) showed comparable performance to CA-125 in
differentiating early stage ovarian cancer from normal
controls [26].
Importantly, none of the above mentioned five pro-
teins have been examined at the peptide level in ovarian
cancer. The endogenous peptides corresponding to each
protein may well have higher diagnostic sensitivity or
specificity than those reported thus far. Future studies
along these lines are warranted.
Candidates previously studied in ovarian cancer
Four of our top candidates have been previously exam-
ined with respect to OvCa but not as biomarkers. Forexample, vitronectin is an important factor in the pro-
gression of ovarian cancer, and has been previously
assayed in ascites fluid [27]. More importantly, cleavage
of vitronectin and fibronectin into small fragments (me-
diated by MMP-2) is a key initiator of metastasis in
ovarian cancer [28]. The generation of these fragments
during disease progression lends support to our finding
of vitronectin-derived peptides in ovarian cancer sam-
ples but not in the benign controls. Endogenous peptide
levels of vitronectin in biological fluids requires further
investigation.
Talin-1 has been previously implicated in serous ovar-
ian carcinoma, particularly in its development and pro-
gression of metastasis [29]. A recent study found that a
specific microRNA, miR-9, which directly targets talin-1,
acts as a tumor suppressor in ovarian cancer [29].
EGF containing fibulin-like extracellular matrix pro-
tein 1 was identified as overexpressed in chemoresistant
OvCa tissue using quantitative proteomics [30].
Finally, transketolase is involved in the pentose phos-
phate shunt and aerobic glycolysis, the primary source
of energy for most fully transformed carcinomas [31].
Expression of Transketolase-like protein 1 (TKTL1), a
similar protein to transketolase, was elevated in serous
papillary ovarian adenocarcinomas [31]. The study found
that expression of TKT1 was also shown to predict poor
prognosis.
None of the above mentioned four candidates have been
investigated as possible biomarkers in ovarian cancer, at
either the protein or peptide levels.
Candidates not previously studied in ovarian cancer
Alpha-mannosidase has been previously identified in the
peritoneal fluid of patients with gynecologic cancers and
pelvic inflammatory disease, but has never been studied
Bery et al. Clinical Proteomics 2014, 11:13 Page 7 of 9
http://www.clinicalproteomicsjournal.com/content/11/1/13specifically in ovarian cancer [32]. Lastly, there is no
existing literature on Apolipoprotein F in ovarian cancer.
Haptoglobin: revisiting a high-abundance protein at the
peptide level
Haptoglobin is a high-abundance serum protein, and has
been extensively studied for use as an OvCa marker [33,34],
but has never before been studied at the peptide level. In
this study, peptides originating from haptoglobin were
found exclusively in the three ovarian cancer samples. We
identified 47 such peptides in total. Figure 4 displays a sche-
matic representation of identified peptides from the hapto-
globin protein in the three OvCa samples, shaded to
highlight identified peptide sequences along the length of
the entire protein. We noticed that there were five con-
served sequences common to at least two of the OvCa
samples. Peptides sharing this common “protein core” may
have diagnostic utility and merit further investigation. No
peptides from haptoglobin were identified in the three
benign samples.
Summary
Most of the 12 candidates discussed above have either been
studied as OvCa biomarkers at the protein level or are im-
plicated in OvCa pathogenesis. Studying some candidates
via selected reaction monitoring quantitative mass spec-
trometry at the peptide level may reveal novel OvCa bio-
markers. Assays for these peptides in various biological
fluids are currently under development.
Conclusion
In this study, we employed a new experimental workflow to
elucidate the peptidome of ovarian cancer ascites fluid. Our
strategy identified over 2000 endogenous peptides and is, to
the best of our knowledge, the first peptidomic study of
ovarian cancer ascites. Comprising 777 unique peptides
found exclusively in OvCa ascites, our work is the first step
towards identifying novel OvCa-specificpeptides. Indeed,
each of our 12 promising candidates requires further verifi-
cation and validation using quantitative selected reaction
monitoring assays on a larger OvCa cohort. The fragmenta-
tion pattern of haptoglobin in OvCa and its corresponding
degradome also merit further investigation.Figure 4 Peptides identified from haptoglobin. A schematic representa
peptides identified per sample. No peptides were identified in the benignMethods
Sample collection and preparation
Ascites fluid was obtained from 3 late-stage serous epi-
thelial ovarian cancer patients and 3 patients with cir-
rhosis of the liver, after written informed consent and
institutional ethics board approval. REB approval is from
University Health Network Research Ethics Board. For
each patient, approximately 1 L of ascites fluid was col-
lected via paracentesis. The samples were aliquoted into
50 mL tubes, centrifuged, and the supernatant was iso-
lated and frozen in −80°C immediately (approximately
3 hours from the time of sample collection to freezing
the supernatant). Samples were stored at −80°C until
further analysis.
Before sample preparation, ascites samples were thawed
and vortexed to re-suspend any precipitate. All specimens
(cases and controls) were processed in parallel, using the
same lot of reagents and columns, to minimize bias in sam-
ple preparation. The samples were centrifuged at 17 000 g
for 10 minutes, then supernatants were diluted in phos-
phate buffered saline (Multicell PBS 1×) to bring the total
protein concentration down to 1 mg/mL for each sample
(this equated to approximately 20 μL of starting volume for
each biological replicate). A final concentration of 2 mM of
dithiothreitol from Sigma-Aldrich was added and the sam-
ples were incubated at room temperature before a final
concentration of 4 mM iodoacetamide was added. Fifteen
millilitres of the ascites fluid was then concentrated using a
Vivaspin 20 mL ultrafiltration spin column with a 10 kDa
cutoff membrane (Sartorius Stedim Biotech), according
to the manufacturer’s instructions (columns were pre-
equilibrated with water before use).
The flow-through obtained after concentration was acid-
ified by drop-wise addition of formic acid to pH 3. The
samples were then passed through a hydrophilic-lipophilic-
balanced reversed-phase cartridge (Oasis HLB). The cart-
ridge (1 cc (30 mg); Waters cat# WAT094225) was pre-
equilibrated with 1 mL 90% acetonitrile (ACN), 0.1% formic
acid. The cartridge was then washed with 5 mL of Buffer A
(5% ACN, 0.1% formic acid), before application of the acid-
ified sample. Following the loading of sample, the cartridge
was washed again with 5 mL of Buffer A. Peptides were
eluted with the addition of 0.5 ml of 60% ACN, 0.1% formiction of the haptoglobin protein. The highlighted areas reveal the
samples.
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200 μL via lyophilization.
Strong cation exchange chromatography
The sample was diluted in mobile phase A (0.26 M for-
mic acid in 5% ACN) to bring the starting volume up to
1 mL prior to injection into a PolySULFOETHYL A co-
lumn with a 200-Å pore size and diameter of 5 μm (The
Nest Group, Inc.) containing a hydrophilic, anionic poly-
mer (poly-2-sulfethyl aspartamide). A 1 hour separation
was performed on an HPLC system (Agilent 1100) using
a mobile phase B containing 0.26 M formic acid in 5%
ACN and 1 M ammonium formate. The eluate was
monitored at a wavelength of 280 nm. Seven fractions
per sample were collected at a flow rate of 200 μL/min.
Mass spectrometry
The resulting fractions were desalted on an Omix C18
pipette tip (Varian) and eluted in 5 μL of buffer B (70%
acetonitrile, 0.1% formic acid). After elution, we added
80 μL of buffer A (0.1% formic acid) to each sample be-
fore loading 40 μL of each onto a 2-cm C18 trap col-
umn, packed with Varian Pursuit (5 μm C18), using the
EASY-nLC system (Proxeon Biosystems). Peptides were
eluted from the trap column onto a resolving 5-cm ana-
lytical C18 column packed with Varian Pursuit (3 μm
C18) with an 8 μm tip (New Objective). This LC setup
was coupled online to an LTQ-Orbitrap XL (Thermo
Fisher Scientific) mass spectrometer using a nano-
electrospray ionization source (Proxeon Biosystems).
Each fraction underwent a 54-min gradient, and eluted
peptides were subjected to 1 full scan (350–2000 m/z) in
the Orbitrap at 60 000 resolution, followed by top 6
data-dependent MS/MS scans in the linear ion trap.
With the use of charge-state screening and preview
mode, unassigned charge states were rejected.
Data analysis
Raw files were used to generate Mascot Generic Files
(MGF) through extract_msn on Mascot Daemon (version
2.2.2). Once generated, MGFs were searched with X!
Tandem (Global Proteome Machine Manager; version
2006.06.01) to confer peptide identifications. Searches
were conducted against the non-redundant Human IPI
database (v.3.71) which contains a total of 173,490 for-
ward and randomized protein sequences and using the
following parameters for GPM: no enzyme ([X]|[X])
cleavages, 50 missed cleavage sites allowed, 7 ppm pre-
cursor ion mass tolerance, 0.4 Da fragment ion mass
tolerance, fixed modifications of carbamidomethylation
of cysteines, and variable modification of oxidation of
methionines (oxM). The X!Tandem (XML files) were
then integrated through the Scaffold 2 software (version
2.06; Proteome Software Inc., Portland, Oregon). False-discovery rates were calculated as the number of peptides
identified by the randomized reverse database divided by
the total number of identified peptides.
Additional files
Additional file 1: Detailed information on peptides (A) and proteins
(B) identified in all 6 studied samples.
Additional file 2: Detailed information on the 777 peptides (A) and
59 protiens (B) identified only in the three OvCa samples.
Additional file 3: A detailed spectrum report of all identified
peptides (including data about peptide modifications).
Additional file 4: List of overlapping proteins with other
publications.
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